Last reviewed · How we verify
Lopinavir/Ritonavir plus Lamivudine/Zidovudine
Lopinavir/Ritonavir plus Lamivudine/Zidovudine is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by University of Cologne. It is currently in Phase 3 development for HIV-1 infection.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication. Used for HIV-1 infection.
At a glance
| Generic name | Lopinavir/Ritonavir plus Lamivudine/Zidovudine |
|---|---|
| Sponsor | University of Cologne |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Lopinavir and ritonavir are protease inhibitors that block HIV protease, preventing the maturation of infectious viral particles. Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors that block the enzyme responsible for converting HIV RNA into DNA, preventing viral integration into host cells. Together, this triple-drug regimen targets multiple steps of the HIV replication cycle.
Approved indications
- HIV-1 infection
Common side effects
- Diarrhea
- Nausea
- Lipid abnormalities
- Hepatotoxicity
- Pancreatitis
- Peripheral neuropathy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
- Antiretroviral Regime for Viral Eradication in Newborns (PHASE4)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopinavir/Ritonavir plus Lamivudine/Zidovudine CI brief — competitive landscape report
- Lopinavir/Ritonavir plus Lamivudine/Zidovudine updates RSS · CI watch RSS
- University of Cologne portfolio CI
Frequently asked questions about Lopinavir/Ritonavir plus Lamivudine/Zidovudine
What is Lopinavir/Ritonavir plus Lamivudine/Zidovudine?
How does Lopinavir/Ritonavir plus Lamivudine/Zidovudine work?
What is Lopinavir/Ritonavir plus Lamivudine/Zidovudine used for?
Who makes Lopinavir/Ritonavir plus Lamivudine/Zidovudine?
What drug class is Lopinavir/Ritonavir plus Lamivudine/Zidovudine in?
What development phase is Lopinavir/Ritonavir plus Lamivudine/Zidovudine in?
What are the side effects of Lopinavir/Ritonavir plus Lamivudine/Zidovudine?
What does Lopinavir/Ritonavir plus Lamivudine/Zidovudine target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: University of Cologne — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Compare: Lopinavir/Ritonavir plus Lamivudine/Zidovudine vs similar drugs
- Pricing: Lopinavir/Ritonavir plus Lamivudine/Zidovudine cost, discount & access